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Introduction
Overweight and obesity is a health threat of increasing concern and has become one of the biggest preventable epidemic diseases worldwide. According to the World Health Organization (WHO), 38% of adult men and 40% of adult women were overweight in 2014 while the worldwide prevalence of obesity more than doubled between 1980 and 2014 (http://www.who. int/mediacentre/factsheets/fs311/en/). A large array of sequelae linked to obesity, including hypertension, diabetes and coronary heart disease, put an increasing socioeconomic and financial burden on society and health systems by causing loss of working hours and an increase in healthcare costs [1] [2] [3] [4] [5] . Research on obesity is urgently needed to improve our understanding of the pathophysiology of this disease and to establish preventive strategies and effective treatment regimens. There are two common treatment options for weight loss: conservative dietary intervention and surgery such as Roux-en-Y gastric bypass (RYGB). For so far unknown reasons some obese individuals benefit more from dietary intervention than RYGB and vice versa [6] . Individual biomarkers for predicting weight loss to help select the optimal treatment approach are not yet available.
The results of pharmacological studies and animal data show that the neurotransmitter system, i.e., brain monoamines, are fundamentally involved in the pathophysiology of obesity [7, 8] . Understanding how these systems affect eating behavior and obesity may allow prediction of the success of weight loss on an individual basis and therefore provide more targeted interventions for the treatment of obesity.
Studies on obesity have so far mainly focused on the central dopamine [9, 10] and serotonin systems [11] . Only a few studies have investigated the role of noradrenaline (NA) in obesity including the development of potential anti-obesity drugs that target NA transmission such as nisoxetine and sibutramine [12, 13] . Both are inhibitors of the NA reuptake site, the NA transporter (NAT), which regulate and terminate NA-mediated neurotransmission by removing NA from the synaptic cleft at presynaptic reuptake sites and providing NA in presynaptic cells for subsequent transmission [14] . It has been shown that cerebral NA neurons and NAT are not confined to synaptic terminals but are also located alongside axons and thus form a neurotransmitter system that in various brain regions modulates alertness, arousal, learning and memory, and thereby influences the brain motivational system [15] . Thus it seems to be important to assess the integrity and function of the brain NA system to determine whether changes in NAT correlate with increased body mass index (BMI) and obesity and whether NAT availability could serve as a predictor for individual treatment selection.
Among selective radioligands for assessing the activity of t he N A s y s te m in v i v o u si n g P E T, (S , S ) -
, a highly selective NAT ligand for brain imaging in humans, has been used to estimate NAT availability by determining its binding potential. The first PET imaging studies using [ 11 C]MRB showed that NAT availability in human obese individuals is lower than or the same as in non-obese controls depending on the sample selection method and the method of analysis [16] [17] [18] . These findings are, however, still considered preliminary and do no clarify whether changes in NAT and central NA transmission is related to the pathophysiology of obesity or whether the activity of the NA system is modifiable along with changes in body weight (e.g., by diet and/or bariatric intervention).
The aim of this study was therefore to further investigate longitudinally whether NAT availability is a stable trait in obese individuals or is altered by interventions. Therefore, we used PET with [ 11 C]MRB in obese and non-obese individuals, well-matched for age and sex, to assess NAT availability before and after 6 months aiming to explore whether NAT availability correlates with changes in body weight and consequently whether it could serve as a predictor of successful weight loss.
Materials and methods

Subjects
Twenty Caucasian participants comprising ten highly obese and ten non-obese otherwise healthy nondepressed individuals underwent PET with [ 11 C]MRB and MRI at baseline and a second PET scan after 6 months of dietary intervention in the obese group or no intervention in the non-obese group. The obese individuals had a BMI of 42.4 ± 3.7 kg/m 2 (which corresponds to WHO class III obesity) and a mean age of 34 ± 9 years. Ten non-obese individuals with a mean BMI of 23.9 ± 2.5 kg/m 2 and free of any medication or illicit drugs were matched for age (33 ± 10 years) and sex (four women in both groups) as described previously [18] . Other exclusion criteria were: eating or psychiatric disorder as assessed by two institutional psychiatrists/neuropsychologists by structured clinical interview, neurological disease, history of head trauma, vascular encephalopathy, malignant hypertension, insulin-dependent diabetes or a medical condition that could alter brain function, use of another intervention to promote weight loss, use of nutritional supplements during the last 2 months, a history of alcohol or drug misuse, pregnancy or breastfeeding and general contraindications for PET or MRI studies, e.g., claustrophobia or the presence ferromagnetic materials [17, 18] . The amount of alcohol and/or nicotine consumption was recorded in both groups. Following individual screening for study eligibility and after obtaining written informed consent, all participants underwent a general physical examination including height and weight measurements for calculation of BMI and neuropsychological assessments. Structural MRI data were acquired using a 3-T Siemens scanner (Erlangen, Germany) as described previously [18] for the exclusion of brain pathologies and PET/MRI data coregistration.
Neuropsychological assessments
The neuropsychological assessment instruments included validated German language versions of the Beck Depression Inventory (BDI) [19] , Barrett Impulsiveness Scale (BIS-11) [20] , FEV-II (BFragebogen zum Ernährungsverhalten^), the German version of the Dutch Eating Behaviour Questionnaire DEBQ [21] , Eating in the Absence of Hunger (EAH) [22] , Eating Hedonics Questionnaire (EHQ) [23] , Yale Food Addiction Scale (YFAS) [24] and the Adult Temperament Questionnaire (ATQ) [25] .
Dietary intervention
The dietary intervention program for obese study participants was performed and monitored by members of the Obesity Outpatient Unit of the Integrated Research and Treatment Center (IFB) AdiposityDiseases. The intervention focused on three activities: nutritional counseling, physical training and psychological coaching.
Image acquisition and processing
Radiotracer preparation and PET imaging were performed with a standard protocol [18] . Briefly, [ 11 C]MRB was synthesized according to the method of Li et al. [16] . The mean injected mass was 0.03 ± 0.04 μg/kg. PET data were acquired over 120 min after intravenous bolus injection of 361 ± 9 MBq [11C]MRB (baseline and follow-up) using an ECAT EXACT HR+ scanner (Siemens, Erlangen, Germany). Further PET and MRI data processing was performed after spatial reorientation of individual MRI datasets of each subject by rigid transformation onto a standard brain dataset to the anterior commissure-posterior commissure line similar to the Talairach space using PMOD version 3.3 (PMOD Technologies, Zurich, Switzerland). Volumes of interest (VOIs) were then manually drawn on consecutive transverse slices of the reoriented individual MRI datasets [18] . PET data were corrected for head motion artifacts using Statistical Parametric Mapping (SPM) software (Wellcome Trust Centre for Neuroimaging, London, UK) and then coregistered with the individual MRI data, with respect to the related VOI set, to obtain the corresponding tissue time-activity curves (TACs) from the dynamic PET data via PMOD. Because head movements of the study participants increased towards the end of the scan period (120 min) we only used TACs up to 90 min (frames 4 to 23) for multilinear regression analysis which were then analyzed by applying a multilinear reference tissue model with two parameters (MRTM2) [26] and the occipital cortex as the reference region [27] to calculate binding potential BP ND . Parametric BP ND images were generated in PMOD using the implemented MRTM2 model with the previously calculated TAC-based clearance rate k2′ (here k2′ = 0.0238 min
) as a fixed constant.
VOI-based analysis
To identify significant associations between changes in BP ND (BP NDfollowup − BP NDbaseline = ΔBP ND ) and changes in BMI (BMI baseline − BMI followup = ΔBMI), correlations between ΔBP ND of these regions for each hemisphere individually and ΔBMI were determined.
Voxel-based analysis for outcome prediction
For voxel-based analysis, which was performed with an exploratory approach to test whether baseline BP ND data can predict weight loss after 6 months intervention, spatial normalization was carried out in SPM. To this end, the parameters from the T1-based normalization to the T1-weighted SPM template of the co-registered MRI data were applied to the BP ND images. Subsequent smoothing was performed using a gaussian filter kernel with 8 mm full-width at half-maximum. Voxel-wise regression analysis was performed with SPM to investigate the association of NAT availability at baseline with ΔBMI as a variate. Voxels exceeding a threshold of p < 0.005 (uncorrected, k > 50 voxels) were considered significant. Six cluster-based regions on each hemisphere were selected based on brain regions known to be relevant in obesogenicity [28, 29] : hippocampal, paracentral, periinsular, midbrain, dorsolateral prefrontal and putaminal.
Statistical analysis
Data were tested for normality of distribution using the Shapiro-Wilk test and the Levene test for homogeneity of variance. Differences in normally distributed data were tested using Student's t test and in not normally distributed data using the Mann-Whitney test. Pearson product moment correlation was used to identify significant associations between ΔBP ND and ΔBMI. Analyses were performed with a significance level of p < 0.05.
Results
Changes in BMI and body weight at 6 months
The period between baseline and follow-up was 6.7 ± 1.5 months. Overall, the non-obese controls showed no changes in BMI (ΔBMI); p = 0.85) over the study period. One non-obese control subject was excluded due to severe weight loss (>10%). In the obese group 6 months of dietary intervention led to a significant reduction in BMI of 4.7 ± 6.9 kg (p = 0.03; percentage weight loss 3.7%; Table 1 ). All participants except one in the obese group regularly attended the interventional program. Two of the obese individuals gained weight over time (percentage weight gain 4.0% and 4.4%).
Neuropsychological assessments at baseline and at 6 months
Obese individuals tended to have a higher BDI score at baseline than non-obese individuals (Table 2) . Obese individuals showed a moderate, nonsignificant reduction in BDI scores after weight loss (45.5%, p = 0.1). Neuropsychological assessment scores were not significantly different between obese and non-obese individuals as indicated in Table 2 , neither at baseline nor at the time of follow-up.
VOI-based analysis in obese individuals
Overall, VOI-based analysis showed no significant changes in BP ND in specific brain regions after 6 months of treatment. ΔBP ND was negatively correlated with changes in BMI in the right insula (R 2 = 0.49, p = 0.03) and the left hippocampus (R 2 = 0.46, p = 0.03; Fig. 1 ), indicating that weight loss is associated with an increase in BP ND . There were no significant correlations between ΔBP ND and ΔBMI in the other regions. In particular, the correlation between ΔBP ND and ΔBMI was not statistically significant in the left insula 
Voxel-based analyses of obese individuals
Voxel-wise regression analyses revealed that BP ND at baseline significantly predicted the amount of weight loss during the dietary intervention (p < 0.005; Fig. 2 ). Thus, cluster-based analysis (combined, bihemispherical) revealed strong negative correlations between BP ND at baseline and ΔBMI in the hippocampal area (R 2 = 0.80, p < 0.0001; Fig. 2b ), the paracentral region (R 2 = 0.74, p = 0.004; Fig. 2c ), the periinsular region (R 2 = 0.70, p = 0.004; Fig. 2d ), the midbrain (R 2 = 0.71, p = 0.002; Fig. 2e ), the dorsolateral prefrontal region (R 2 = 0.68, p = 0.002; Fig. 2f ), and the putaminal area (R 2 = 0.65; p = 0.001; Fig. 2g ) indicating that low baseline BP ND is associated with higher weight loss after 6 months.
Discussion
hippocampus after weight loss that was correlated with the change in BMI achieved. This shows that NA transmission and presynaptic NAT are modifiable through dietary interventions that affect body weight. Furthermore, our findings indicate that NAT availability in these regions can predict the amount of weight loss after dietary intervention in obese individuals.
The changes in these distinct regions are supported by the findings of various studies of the relationship between the insula and human obesity showing that the insula plays a key role in eating behavior as a center for interoception and as part of the primary gustatory cortex [30, 31] . Thus, the insular cortex is associated with a variety of functions related to food intake, responses to flavor and taste, and craving for food [32, 33] . As an example, Del Parigi et al. showed regional cerebral blood flow as a marker of neural activity increases in the insula in response to sensory stimulation with food in obese individuals [34] . In addition to these observations of a major role of the insula in the pathophysiology of obesity, our findings show that these changes might be associated with the activity of the NA system.
Obese individuals had lower NAT availability in the hippocampus after the dietary intervention which may cohere with changes in reinforcement learning found in obesity [35] , and in the regulation of food intake [36] , but also in sensing the metabolic and hormonal status of the body [37] . Our findings indicate that the hippocampus may play a role in the pathophysiology of obesity by integrating learning and memory circuits that is basically driven by NA-mediated sensory processing [38] . Thus both areas, the insula and the hippocampus, have an important association with the obese state, which means that neurological abnormalities in these regions precede, follow or accompany obesity. Most importantly, these functions seem to be changeable and reversible with weight loss. However, we did not observe statistically significant associations between changes in NAT availability and changes In order to further disentangle the role of the brain NA system in the pathophysiology of obesity, the primary objective of this study was to determine whether a dietary intervention that led to weight loss was associated with changes in central NAT availability as an indicator of NA system activity. Using PET with the NAT-selective radiotracer [ 11 C]MRB, we found an association between deliberately induced weight loss and regional changes in brain NAT availability in highly obese, otherwise healthy humans. These regions included the hippocampal, the paracentral, the periinsular, the midbrain, the dorsolateral prefrontal and the putaminal areas. In contrast to non-obese individuals, who did not show changes in NAT availability in the absence of an intervention, obese individuals showed a significant increase in the right insula and left in BMI either in the contralateral insula or in the contralateral hippocampus. More studies on the association between NA system activity in vivo and changes in body weight are needed to draw a definite conclusion.
As a secondary objective of the study, we investigated the relationship between NAT availability in the brain and behavioral changes after the dietary intervention that included assessment of depressivity (BDI), emotional eating (FEV-II, DEBQ, EHQ, EAH) and impulsiveness (BIS-11, ATQ) at baseline and at follow-up. Although none of the neuropsychological assessment scores changed significantly, obese individuals' scores on the BDI indicating subthreshold depressive symptomatoloy compared with non-obese individuals at baseline did slightly improve after weight loss towards values in non-obese individuals. However, these moderate changes in BDI scores between baseline and the follow-up examination were not related to changes in NAT in our study, suggesting that depression might accompany, but is not necessarily correlated with, obesity.
In summary, to our knowledge this is the first in vivo study to investigate longitudinal changes in NAT availability in human obese individuals after weight loss after a dietary intervention and the putative prediction of weight loss based on NAT availability prior to the intervention. This suggests that central NAT as measured on PET with a highly selective radiolabeled NAT ligand could serve as a biomarker to predict successful weight loss after a dietary intervention and may help identify patients who are less likely to achieve weight loss with a conservative dietary intervention. However, whether treatment response can be predicted by baseline NAT BP ND needs confirmation in studies with larger cohorts including more patients who do not respond to treatment. It would be of further interest to investigate whether NAT availability also changes in obese patients following bariatric surgery, which is the treatment option with at least initially the largest effects on body weight. Such studies recruiting patients undergoing bariatric surgery have already been performed focusing on other distinct neurotransmitters, the brain μ-opioid receptor and dopamine D2 receptor availability [39] as well as serotonin [11] . Neurotransmitter studies including measurement of NAT availability with PET might help determine if dietary intervention or bariatric surgery is likely to have a higher success rate in an individual trying to lose weight, driving a new approach to individualized therapy.
Conclusion
In highly obese individuals weight loss is associated with changes in central NAT availability in regions known to be involved in neural circuits that mediate eating behavior. Our data also indicate that weight loss may be predicted by measuring regional NAT availability prior to intervention. If confirmed, such measurement of NAT availability with PET may serve as an individual biomarker to predict the likelihood of achieving weight loss after dietary intervention and offer the possibility of identifying patients who will or will not benefit from dietary intervention. Whether measurement of NAT availability with PET is also able to predict the success of other antiobesity treatments such as bariatric surgery and might therefore be used in the future in formulating personalized interventional strategies in individuals with obesity needs to be evaluated in comparative prospective studies. 
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